Advertisement

Topics

Economic Evaluation of Heart Failure Management in Colombian Clinics

2014-07-23 21:09:52 | BioPortfolio

Summary

Cost effectiveness analysis of local management of patients diagnosed with heart failure disease compared with an ideal guideline-based management.

Study Design

Observational Model: Cohort, Time Perspective: Retrospective

Conditions

Heart Failure

Status

Completed

Source

AstraZeneca

Results (where available)

View Results

Links

Published on BioPortfolio: 2014-07-23T21:09:52-0400

Clinical Trials [2182 Associated Clinical Trials listed on BioPortfolio]

“ALOFT – Aliskiren Observation of Heart Failure Treatment”: Efficacy and Safety of Aliskiren Added on Top of Standard Therapy in Adults (≥ 18 Years) With Stable Heart Failure

This study was designed to determine if patients, who have both high blood pressure and heart failure and are currently receiving drug treatment for heart failure, have an improvement in t...

Curing Atrial Fibrillation in Heart Failure

Heart failure is a condition that occurs when the heart muscle weakens and no longer contracts normally. Half of these patients have an irregularity of heart rhythm called atrial fibrilla...

Aldosterone Blockade in Heart Failure

Heart failure causes significant morbidity and mortality and is the most rapidly increasing cardiovascular diagnosis in North America overall prevalence is estimated at 0.4% to 2.4%. Rece...

Get With The Guidelines-Heart Failure Registry

Get With The Guidelines-Heart Failure is designed to improve the quality of care in patients hospitalized with heart failure. The program aims to help ensure that eligible patients are ini...

Study of Left Ventricular Dyssynchrony in Heart Failure Patients

Heart failure has become one of the major epidemics of the modern era. Despite optimal standard drug therapy, the prognosis of patients with heart failure remains poor. Patient with Heart...

PubMed Articles [6661 Associated PubMed Articles listed on BioPortfolio]

Common Postoperative Heart Transplant Complications.

Heart failure or congestive heart failure remains a major public health concern on the global scale. End-stage heart failure is a severe disease where the heart is unable to pump enough oxygen and nut...

In-hospital and 3-year outcomes of heart failure patients in South India: The Trivandrum Heart Failure Registry.

Long-term data on outcomes of participants hospitalized with heart failure (HF) from low and middle-income countries are limited.

Prospective evaluation of integrated device diagnostics for heart failure management: results of the TRIAGE-HF study.

The primary aim of the TRIAGE-HF trial was to correlate cardiac implantable electronic device-generated heart failure risk status (HFRS) with signs, symptoms, and patient behaviours classically associ...

Atrial remodelling in heart failure: recent developments and relevance for heart failure with preserved ejection fraction.

Natriuretic Peptides as Biomarkers of Treatment Response in Clinical Trials of Heart Failure.

The lack of reliable predictors of the efficacy of drugs and devices in heart failure (HF) has presented a major hurdle to the development and evaluation of novel therapies.

Medical and Biotech [MESH] Definitions

A heterogeneous condition in which the heart is unable to pump out sufficient blood to meet the metabolic need of the body. Heart failure can be caused by structural defects, functional abnormalities (VENTRICULAR DYSFUNCTION), or a sudden overload beyond its capacity. Chronic heart failure is more common than acute heart failure which results from sudden insult to cardiac function, such as MYOCARDIAL INFARCTION.

Enlargement of the HEART, usually indicated by a cardiothoracic ratio above 0.50. Heart enlargement may involve the right, the left, or both HEART VENTRICLES or HEART ATRIA. Cardiomegaly is a nonspecific symptom seen in patients with chronic systolic heart failure (HEART FAILURE) or several forms of CARDIOMYOPATHIES.

Heart failure caused by abnormal myocardial contraction during SYSTOLE leading to defective cardiac emptying.

Heart failure caused by abnormal myocardial relaxation during DIASTOLE leading to defective cardiac filling.

Agents that have a strengthening effect on the heart or that can increase cardiac output. They may be CARDIAC GLYCOSIDES; SYMPATHOMIMETICS; or other drugs. They are used after MYOCARDIAL INFARCT; CARDIAC SURGICAL PROCEDURES; in SHOCK; or in congestive heart failure (HEART FAILURE).

More From BioPortfolio on "Economic Evaluation of Heart Failure Management in Colombian Clinics"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topic

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...


Searches Linking to this Trial